Jazz, Concert Pharma sign license deal for narcolepsy drug development
Under the agreement, Jazz will develop Concert’s deuterium-modified sodium oxybate (D-SXB) compounds, including C-10323, and will have worldwide commercial rights to C-10323 as well as principal responsibility for